Search

everythinglearnresearchcommunity

for

Search:↓

Older men with severe symptoms and larger prostates should focus on prevention, using finasteride and alpha-blockers to manage acute urinary retention.

Dutasteride is more effective than finasteride in reducing urinary retention and surgery risks in people aged 65 and older.

Early intervention for acute urinary retention can reduce costs and improve care.

Finasteride reduces urinary issues and surgery need in men with enlarged prostates by over 50%.

Drugs that block DHT production can effectively treat enlarged prostate and improve urinary issues with some sexual side effects.

Dutasteride is effective for treating prostate enlargement and reducing related surgery risk, but is not approved for preventing prostate cancer.

COVID-19 worsens urinary symptoms in men with benign prostatic hyperplasia, requiring careful treatment management.

"Flosin – Prostamol Uno" effectively manages BPH symptoms with fewer side effects.

Evidence-based urology improved treatment and quality of life for conditions like BPH by shifting from surgery to effective medications like finasteride and dutasteride.

Finasteride reduces PSA levels by around 40-50% in BPH patients.

Finasteride lowers risk of urinary issues and surgery by over 50% in 4 years.

5-alpha reductase inhibitors slightly reduce urinary symptoms and may lower surgery and acute retention risks in men.

Finasteride improves urinary symptoms and quality of life in BPH patients, especially with larger prostate size.

Tamsulosin works faster, but both drugs have similar effects after 6 months.

Dutasteride effectively treats benign prostatic obstruction, improves urinary flow, reduces prostate size, and may prevent prostate cancer, but can cause sexual side effects.

Both dutasteride and finasteride improve urinary symptoms, but dutasteride may be better at reducing the risk of prostate surgery and sudden inability to urinate.

Finasteride effectively reduces the need for surgery and urinary issues in men with BPH over the long term.

Finasteride is a cost-effective option for treating BPH, reducing risk of urinary issues and surgery.

Finasteride effectively treats benign prostatic hyperplasia by reducing prostate size and improving urinary symptoms.

Taking 5-ARI before prostate laser surgery may lead to more blood changes, longer surgery, and more urinary issues.

5ARIs effectively treat and manage BPH by reducing prostate size and symptoms.

Combining medications is more effective for treating benign prostatic syndrome symptoms.

Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.

Blocking the enzyme that turns testosterone into DHT can safely and effectively treat enlarged prostate.

Dutasteride effectively treats enlarged prostate, reduces prostate cancer risk, and promotes hair regrowth with few side effects.

Finasteride effectively reduces prostate size and lowers surgery risk in men with benign prostatic hyperplasia.

Dutasteride effectively treats benign prostatic hyperplasia but isn't approved for preventing prostate cancer.

Dutasteride reduces DHT more than finasteride, but both drugs improve BPH symptoms similarly.

Combination therapy for BPH is cost-effective, especially for men with larger prostates.